LEGNLegend Biotech Corporation

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t

With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even opens.

CARVYKTI sales surged 50% globally as company swung to profitability.

Legend Biotech achieves company-wide profitability with adjusted net income of $63 million, while advancing its promising in vivo CAR-T platform.

Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.

Legend Biotech Corporation (NASDAQ:LEGN) shares gained 5. 5% in pre-market trading on Tuesday after the pharmaceutical company delivered better-than-expected second-quarter earnings and revenue, supported by continued growth in CARVYKTI sales.

Legend Biotech (NASDAQ:LEGN) reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company’s first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call. Interim Chief Executive Officer Alan Bash said

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad

Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

Legend Biotech stock has seen a steep share price decline over the past few years, yet the latest valuation checks still point to shares screening as cheap on several measures. With fresh leadership changes and ongoing focus on its key CAR-T therapy, investors are weighing whether the recent weakness reflects business risk or a disconnect between price and fundamentals. Over the last 3 years, Legend Biotech shares have fallen 74.6%, which places recent valuation interest squarely on whether...

Legend Biotech recently announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and Board member, effective July 24, 2026, with CARVYKTI business unit President Alan Bash appointed as Interim CEO and Dr. Huang staying on briefly as an advisor. This leadership reshuffle at the top of a company built around a single, high-profile CAR-T franchise raises important questions about continuity in execution, partnerships, and global expansion plans. Now we’ll examine how the...

Legend Biotech, listed as NasdaqGS:LEGN, announced that CEO Ying Huang has stepped down. Alan Bash has been appointed as Interim CEO to lead the company through the transition. The leadership change comes at a time when Legend Biotech remains active in the competitive biotech sector. Legend Biotech focuses on developing and commercialising cell therapies, a field that attracts significant attention from both large pharmaceutical companies and specialist biotech investors. Leadership...

Legend Biotech’s CEO stepped down without warning, while Sarepta has appointed a biopharma veteran to take the company forward.

Legend said on Monday that Ying Huang stepped down as chief executive officer and board member effective July 24.

Shares of Legend Biotech fell 14% Monday after the company announced that CEO Ying Huang stepped down and left the board. Legend said in a regulatory filing that Huang’s resignation was not the result of a disagreement with the company, but didn’t say anything more about why he left. Huang said he was departing the company to work with a venture fund focusing on drug development.

Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipeline trouble.